We’re excited to share that Opticyte is entering the final month of our StartEngine campaign.
With over $235,000 raised on StartEngine, plus additional outside investment through a convertible note, our community continues to grow. We’re incredibly proud of the support we’ve received from investors who share our vision to potentially transform patient monitoring and health equity with our VitalO₂ Monitor.
Opticyte’s VitalO₂ technology is designed to provide a new level of visibility for clinicians, which we believe could help them detect oxygen deficiencies earlier and potentially more accurately, regardless of skin tone.
It’s a technology built to help address two of healthcare’s biggest challenges:
– Early detection of life-threatening conditions like sepsis.
– Racial disparities in pulse oximetry performance of current monitors
As we enter this final month, we invite you to learn more about our journey, explore the details on our campaign page, and consider joining us as an investor.
We invite you to consider joining our growing investor community.
Learn more about our work to bring better monitoring to hospitals and help us deliver solutions that we hope will lead to improved outcomes for all patients. https://www.startengine.com/offering/opticyte
Thank you for being part of our community and following along with our journey.
— Lori Arakaki and the Opticyte Team
